Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (298)	12/17/1997 9:46:00 PM
From: flickerful	Read Replies (1) \| Respond to of 756

i look forward to the debriefing. <eom>

To: 5,17,37,5,101,... who wrote (298)	12/18/1997 12:36:00 AM
From: flickerful	Read Replies (1) \| Respond to of 756

nb the last paragraph: 5th March 1996Chiroscience Secures Major Agreement with Knoll (BASF) on Verapamil Isomers Chiroscience Group plc, the world's leading chiral pharmaceutical company, has signed an agreement with Knoll AG (the pharmaceutical division of German conglomerate BASF) on the development and marketing of verapamil isomers which could result in significant revenues to Chiroscience over the next ten years. Chiroscience and Knoll will develop isomer versions of the cardiovascular drug verapamil to provide improved treatments for current and new disease indications. Both companies will contribute research expertise to this joint programme. Pre-clinical studies are under way and the companies expect drug candidates to enter clinical trials by the end of the year. In recognition of technology and patents already developed by Chiroscience, the company will receive an up-front access payment from Knoll, followed by milestone payments at key stages of development. Knoll will be responsible for development and will have exclusive world wide rights to market drugs developed under the collaboration, with Chiroscience receiving royalty payments on sales. Dr John Padfield, Chief Executive of Chiroscience, said: "This is a significant Agreement for Chiroscience, and it is particularly pleasing to work with Knoll who originated verapamil. It follows the announcements in 1995 of the Letter of Intent with Pharmacia & Upjohn and the Agreement with Medeva on single isomer methylphenidate, and demonstrates our continuing ability to attract the interest of pharmaceutical partners." Dr Roberto Gradnik, Business Director Isoptin/Cardiovascular of Knoll, commented: "Verapamil (Isoptinr, Securonr and others) is still our most important product and even after many years has a lot of new things to say. Through this co-operation, which is part of the new philosophy of Knoll to have targeted projects together with specialised companies, we intend to exploit further into the next century the potential of this molecule."